Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling

Inhaled fosamprenavir for laryngopharyngeal reflux: Toxicology and fluid dynamics modeling

Abstract Objectives Approximately 25% of Americans suffer from laryngopharyngeal reflux (LPR), a disease for which no effective medical therapy exists. Pepsin is a predominant source of damage during LPR and a key therapeutic target. Fosamprenavir (FOS) inhibits pepsin and prevents damage in an LPR...

Full description

Bibliographic Details
Main Authors: Alexandra Lesnick, Tina L. Samuels, Donna Seabloom, Beverly Wuertz, Abhilash Ojha, Davis Seelig, Frank Ondrey, Timothy S. Wiedmann, Chris Hogan, Emma Torii, Hui Ouyang, Ke Yan, Guilherme J. M. Garcia, Jonathan M. Bock, Nikki Johnston
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Laryngoscope Investigative Otolaryngology
Subjects:
computational fluid dynamics
dry powder inhaler
laryngopharyngeal delivery
laryngopharyngeal reflux
pepsin
Online Access:https://doi.org/10.1002/lio2.1219

Internet

https://doi.org/10.1002/lio2.1219

Similar Items